{"component": "clause", "props": {"groups": [{"samples": [{"hash": "lVkjGtreDVE", "uri": "/contracts/lVkjGtreDVE#development-information", "label": "Operating Agreement (Bluerock Residential Growth REIT, Inc.)", "score": 27.1464748383, "published": true}, {"hash": "dHfXWxmDFgb", "uri": "/contracts/dHfXWxmDFgb#development-information", "label": "Operating Agreement (Bluerock Residential Growth REIT, Inc.)", "score": 26.4209442139, "published": true}, {"hash": "dQYvJTRjABC", "uri": "/contracts/dQYvJTRjABC#development-information", "label": "Operating Agreement (Bluerock Residential Growth REIT, Inc.)", "score": 25.6132793427, "published": true}], "size": 7, "snippet_links": [{"key": "construction-process", "type": "clause", "offset": [11, 31]}, {"key": "will-provide", "type": "clause", "offset": [43, 55]}, {"key": "to-borrower", "type": "definition", "offset": [56, 67]}, {"key": "br-member", "type": "definition", "offset": [81, 90]}, {"key": "copies-of-all", "type": "definition", "offset": [91, 104]}, {"key": "related-information", "type": "clause", "offset": [127, 146]}, {"key": "not-limited", "type": "clause", "offset": [162, 173]}, {"key": "copies-of-the", "type": "clause", "offset": [185, 198]}, {"key": "construction-draws", "type": "clause", "offset": [199, 217]}, {"key": "access-to-the-property", "type": "clause", "offset": [342, 364]}, {"key": "in-connection-with", "type": "clause", "offset": [387, 405]}, {"key": "development-and-construction-of-the-project", "type": "clause", "offset": [410, 453]}], "snippet": "During the construction process, Developer will provide to Borrower, Company and BR Member copies of all Loan-related and draw-related information, including but not limited to monthly copies of the construction draws, construction draws top sheets with budget-versus-actual information to Borrower, Company and BR Member, plus full physical access to the Property and all documentation in connection with the development and construction of the Project.", "hash": "cbeafccc6f7a8643dec0fcd0979bf3c3", "id": 1}, {"samples": [{"hash": "jMT0okhke7w", "uri": "/contracts/jMT0okhke7w#development-information", "label": "License Agreement (Transkaryotic Therapies Inc)", "score": 18.0, "published": true}, {"hash": "2Gxd0j6OTYy", "uri": "/contracts/2Gxd0j6OTYy#development-information", "label": "License Agreement (Transkaryotic Therapies Inc)", "score": 18.0, "published": true}], "size": 4, "snippet_links": [{"key": "regulatory-submissions", "type": "definition", "offset": [26, 48]}, {"key": "development-committee", "type": "definition", "offset": [83, 104]}, {"key": "adverse-event-information", "type": "clause", "offset": [195, 220]}], "snippet": "13 5.3.1. Information for Regulatory Submissions............. 13 5.3.2. Reports to Development Committee................... 14 5.3.3. Regulatory Submissions. .......................... 14 5.3.4. Adverse Event Information.......................... 14 5.4.", "hash": "7849cd1c79a749f8049a20a70d345bea", "id": 2}, {"samples": [{"hash": "kzOsl2t2Mqe", "uri": "/contracts/kzOsl2t2Mqe#development-information", "label": "Collaboration Agreement (Diacrin Inc /De/)", "score": 18.0, "published": true}, {"hash": "7XqMTMiN9ie", "uri": "/contracts/7XqMTMiN9ie#development-information", "label": "Collaboration Agreement (Diacrin Inc /De/)", "score": 18.0, "published": true}], "size": 4, "snippet_links": [{"key": "reports-and-information-exchange", "type": "clause", "offset": [10, 42]}, {"key": "adverse-reaction-reporting", "type": "clause", "offset": [71, 97]}, {"key": "clinical-and-regulatory-audits", "type": "clause", "offset": [132, 162]}, {"key": "regulatory-approval-filings", "type": "clause", "offset": [191, 218]}, {"key": "facilities-visits", "type": "clause", "offset": [258, 275]}], "snippet": "16 5.2.1. Reports and Information Exchange ................. 16 5.2.2. Adverse Reaction Reporting ....................... 17 5.2.3. Clinical and Regulatory Audits ................... 17 5.3. Regulatory Approval Filings .............................. 17 5.4. Facilities Visits ........................................ 18", "hash": "8204975fb043036495dd267bc4bea3c3", "id": 3}, {"samples": [{"hash": "3m2wG82cwME", "uri": "/contracts/3m2wG82cwME#development-information", "label": "License Agreement (Clearside Biomedical, Inc.)", "score": 27.0177955627, "published": true}, {"hash": "46TU1wHm8PF", "uri": "/contracts/46TU1wHm8PF#development-information", "label": "License Agreement (Clearside Biomedical, Inc.)", "score": 25.5968513489, "published": true}, {"hash": "51pKS0d47u8", "uri": "/contracts/51pKS0d47u8#development-information", "label": "License Agreement (Clearside Biomedical, Inc.)", "score": 25.4763851166, "published": true}], "size": 3, "snippet_links": [{"key": "subject-to", "type": "clause", "offset": [15, 25]}, {"key": "other-third-parties", "type": "definition", "offset": [57, 76]}, {"key": "to-development", "type": "clause", "offset": [99, 113]}, {"key": "grant-to-licensor", "type": "clause", "offset": [127, 144]}, {"key": "for-licensor", "type": "clause", "offset": [153, 165]}, {"key": "refer-to", "type": "definition", "offset": [183, 191]}, {"key": "information-delivered", "type": "clause", "offset": [208, 229]}, {"key": "section-127", "type": "clause", "offset": [270, 282]}, {"key": "provide-a", "type": "definition", "offset": [291, 300]}, {"key": "licensed-patents", "type": "definition", "offset": [344, 360]}, {"key": "conditions-of", "type": "clause", "offset": [368, 381]}, {"key": "consistent-with", "type": "definition", "offset": [398, 413]}, {"key": "article-11", "type": "definition", "offset": [414, 424]}, {"key": "efforts-to-license", "type": "clause", "offset": [456, 474]}, {"key": "transfer-to", "type": "clause", "offset": [569, 580]}, {"key": "in-the-event", "type": "clause", "offset": [641, 653]}, {"key": "in-writing", "type": "definition", "offset": [670, 680]}, {"key": "material-economic-terms", "type": "definition", "offset": [684, 707]}, {"key": "a-third-party", "type": "clause", "offset": [713, 726]}, {"key": "grant-of", "type": "definition", "offset": [742, 750]}, {"key": "license-to", "type": "clause", "offset": [753, 763]}, {"key": "company-hereunder", "type": "clause", "offset": [829, 846]}, {"key": "notice-thereof", "type": "clause", "offset": [879, 893]}, {"key": "and-company", "type": "clause", "offset": [905, 916]}, {"key": "good-faith-negotiations", "type": "definition", "offset": [934, 957]}, {"key": "granting-of-rights", "type": "clause", "offset": [995, 1013]}, {"key": "transfer-of-title", "type": "clause", "offset": [1021, 1038]}, {"key": "the-development", "type": "clause", "offset": [1043, 1058]}, {"key": "commercially-reasonable-terms", "type": "definition", "offset": [1094, 1123]}, {"key": "the-foregoing", "type": "definition", "offset": [1219, 1232]}, {"key": "termination-of-this-agreement", "type": "clause", "offset": [1246, 1275]}], "snippet": "COMPANY shall, subject to any rights any Sublicensees or other third parties may have with respect to Development Information, grant to LICENSOR a right for LICENSOR to access and to refer to all Development Information delivered or required to be delivered pursuant to Section 12.7, and to provide a copy thereof to potential licensees of the Licensed Patents (under conditions of confidentiality consistent with Article 11), solely for use in LICENSOR\u2019s efforts to license the Licensed Patents to any third party; LICENSOR shall not be entitled to license, grant, or transfer to any third party any rights in such Development Information. In the event LICENSOR agrees in writing to material economic terms with a third party concerning the grant of a license to such third party under the Licensed Patents formerly licensed to COMPANY hereunder, LICENSOR shall provide written notice thereof to COMPANY and COMPANY shall enter into good faith negotiations with such third party concerning the granting of rights to, or transfer of title in, the Development Information to such third party on commercially reasonable terms, subject to any rights any Sublicensees or other third parties may have with respect to any of the foregoing that survive termination of this Agreement.", "hash": "449f2a42f5cc4623f0976a2630c07bbd", "id": 4}, {"samples": [{"hash": "5karywOejrF", "uri": "/contracts/5karywOejrF#development-information", "label": "Divestiture Agreement (Ophthotech Corp.)", "score": 24.6194381714, "published": true}, {"hash": "75g5NoUea1f", "uri": "/contracts/75g5NoUea1f#development-information", "label": "Research and License Agreement (Archemix Corp.)", "score": 21.0, "published": true}, {"hash": "5ykWD9RkUgN", "uri": "/contracts/5ykWD9RkUgN#development-information", "label": "Research and License Agreement (Nitromed Inc)", "score": 21.0, "published": true}], "size": 3, "snippet_links": [{"key": "will-provide", "type": "clause", "offset": [9, 21]}, {"key": "the-jrc", "type": "clause", "offset": [34, 41]}, {"key": "on-a-quarterly-basis", "type": "definition", "offset": [42, 62]}, {"key": "during-the-research-term", "type": "clause", "offset": [63, 87]}, {"key": "all-material-information", "type": "clause", "offset": [104, 128]}, {"key": "applicable-to", "type": "definition", "offset": [129, 142]}, {"key": "the-field", "type": "clause", "offset": [143, 152]}, {"key": "raw-data", "type": "clause", "offset": [262, 270]}, {"key": "early-selection-criteria", "type": "definition", "offset": [364, 388]}, {"key": "to-exercise", "type": "clause", "offset": [457, 468]}, {"key": "rights-under-this-agreement", "type": "clause", "offset": [473, 500]}, {"key": "sole-discretion", "type": "definition", "offset": [535, 550]}, {"key": "the-license-option", "type": "clause", "offset": [572, 590]}, {"key": "with-respect-to", "type": "clause", "offset": [591, 606]}, {"key": "compound-candidate", "type": "definition", "offset": [632, 650]}, {"key": "the-development", "type": "clause", "offset": [667, 682]}, {"key": "undisclosed-information", "type": "definition", "offset": [729, 752]}, {"key": "archemix-technology", "type": "definition", "offset": [769, 788]}, {"key": "evaluation-of-the-program", "type": "clause", "offset": [841, 866]}, {"key": "evaluation-criteria", "type": "clause", "offset": [904, 923]}, {"key": "appendix-1", "type": "definition", "offset": [951, 961]}, {"key": "without-limitation", "type": "clause", "offset": [963, 981]}, {"key": "program-compounds", "type": "definition", "offset": [1023, 1040]}], "snippet": "ARCHEMIX will provide EYETECH and the JRC on a quarterly basis during the Research Term, with notice of all material information applicable to the Field known to ARCHEMIX about any Program Compound (the \u201cDevelopment Information\u201d), including analysis results and raw data which the JRC should reasonably require to assess whether a given Program Compound meets the Early Selection Criteria or which EYETECH should reasonably require in order for EYETECH (i) to exercise its rights under this Agreement, and (ii) to decide, in EYETECH\u2019s sole discretion, whether to exercise the License Option with respect to such Program Compound or Compound Candidate, as applicable. The Development Information shall also include any previously undisclosed information with respect to ARCHEMIX Technology, which is important for a scientific and commercial evaluation of the Program Compound. EYETECH expects to utilize evaluation criteria such as those set forth on Appendix 1, without limitation, in its assessment of whether to license Program Compounds or Compound Candidates.", "hash": "7e358ba09ec90b34ec59f1f4676c89e7", "id": 5}, {"samples": [{"hash": "5fZ2XRyZ0ws", "uri": "/contracts/5fZ2XRyZ0ws#development-information", "label": "Collaborative Research, Development and Marketing Agreement (GPC Biotech Ag)", "score": 21.0, "published": true}], "size": 3, "snippet_links": [{"key": "development-and-testing", "type": "clause", "offset": [83, 106]}, {"key": "development-compounds", "type": "clause", "offset": [118, 139]}, {"key": "necessary-for", "type": "definition", "offset": [214, 227]}, {"key": "within-thirty", "type": "clause", "offset": [239, 252]}, {"key": "following-the", "type": "definition", "offset": [263, 276]}, {"key": "calendar-quarter", "type": "clause", "offset": [289, 305]}, {"key": "designation-of-a", "type": "clause", "offset": [320, 336]}, {"key": "detailed-report", "type": "clause", "offset": [414, 429]}, {"key": "reporting-obligation", "type": "clause", "offset": [590, 610]}, {"key": "report-to", "type": "clause", "offset": [642, 651]}, {"key": "the-collaborative", "type": "definition", "offset": [652, 669]}, {"key": "policy-setting", "type": "clause", "offset": [670, 684]}, {"key": "day-period", "type": "clause", "offset": [719, 729]}, {"key": "provided-that", "type": "definition", "offset": [731, 744]}, {"key": "report-of-the", "type": "clause", "offset": [755, 768]}, {"key": "oral-presentation", "type": "definition", "offset": [769, 786]}, {"key": "days-after", "type": "definition", "offset": [837, 847]}, {"key": "in-addition", "type": "clause", "offset": [919, 930]}, {"key": "the-contemplated", "type": "clause", "offset": [1021, 1037]}, {"key": "regulatory-submissions", "type": "definition", "offset": [1131, 1153]}, {"key": "prior-to-the", "type": "clause", "offset": [1184, 1196]}, {"key": "date-of", "type": "clause", "offset": [1197, 1204]}, {"key": "amendments-or-supplements", "type": "clause", "offset": [1236, 1261]}, {"key": "business-days-of", "type": "clause", "offset": [1286, 1302]}, {"key": "in-a-timely-manner", "type": "definition", "offset": [1357, 1375]}, {"key": "copies-of", "type": "definition", "offset": [1376, 1385]}, {"key": "requested-by", "type": "clause", "offset": [1456, 1468]}, {"key": "access-to", "type": "clause", "offset": [1528, 1537]}, {"key": "for-review", "type": "clause", "offset": [1628, 1638]}], "snippet": "DuPont Merck shall keep Mitotix informed as to the progress of DuPont Merck in the development and testing of all CDK Development Compounds and CDK Products and the preparing, filing and obtaining of the approvals necessary for marketing. Within thirty (30) days following the end of each Calendar Quarter following the designation of a CDK Development Compound, DuPont Merck shall provide to Mitotix a reasonably detailed report which shall describe the progress of the development and testing of the CDK Products incorporating such CDK Development Compounds. DuPont Merck may satisfy its reporting obligation hereunder by providing an oral report to the Collaborative Policy Setting Committee within such thirty (30) day period, provided that a written report of the oral presentation is delivered to Mitotix no later than thirty (30) days after the oral report is made to the Collaborative Policy Setting Committee. In addition, DuPont Merck shall provide Mitotix with a minimum of three (3) months\u2019 advance notice of the contemplated filing of an IND or an NDA. DuPont Merck shall provide Mitotix with a report on all material regulatory submissions at least forty-five (45) days prior to the date of such submissions, or any major amendments or supplements thereto within ten (10) business days of filing thereof. DuPont Merck shall provide to Mitotix in a timely manner copies of any material regulatory submission, or amendments thereof, reasonably requested by Mitotix or, alternatively shall provide Mitotix reasonable access to each such material regulatory submission or amendments thereof at DuPont Merck\u2019s offices, for review and copying by Mitotix.", "hash": "c0f1eba93e443268b4a71fc1af272b3d", "id": 6}, {"samples": [{"hash": "hYBtgt1QNbd", "uri": "/contracts/hYBtgt1QNbd#development-information", "label": "Research Collaboration and License Agreement (Corixa Corp)", "score": 18.0, "published": true}, {"hash": "2EtW6nwbX4Z", "uri": "/contracts/2EtW6nwbX4Z#development-information", "label": "Research Collaboration and License Agreement (Corixa Corp)", "score": 18.0, "published": true}], "size": 2, "snippet_links": [{"key": "the-development", "type": "clause", "offset": [57, 72]}, {"key": "product-candidates", "type": "clause", "offset": [80, 98]}, {"key": "this-agreement", "type": "clause", "offset": [105, 119]}, {"key": "necessary-for", "type": "definition", "offset": [166, 179]}, {"key": "within-thirty", "type": "clause", "offset": [286, 299]}, {"key": "days-after", "type": "definition", "offset": [305, 315]}, {"key": "calendar-year-period", "type": "definition", "offset": [332, 352]}, {"key": "written-report", "type": "definition", "offset": [408, 422]}, {"key": "development-of-the-product", "type": "clause", "offset": [454, 480]}], "snippet": "CellPro shall keep Corixa informed as to the progress of the development of all Product Candidates under this Agreement and the filing and obtaining of the approvals necessary for marketing. Once CellPro has selected a Product Candidate and proceeded with the development thereof, then within thirty (30) days after the end of each calendar year period, CellPro shall provide to Corixa a reasonably detailed written report describing the progress of the development of the Product Candidate.", "hash": "47c3aa676fba77dd552b365bdda1208e", "id": 7}, {"samples": [{"hash": "8r28t62t6nv", "uri": "/contracts/8r28t62t6nv#development-information", "label": "License Agreement (resTORbio, Inc.)", "score": 29.0410671234, "published": true}, {"hash": "goCHXCcIWnj", "uri": "/contracts/goCHXCcIWnj#development-information", "label": "License Agreement (resTORbio, Inc.)", "score": 28.9151268005, "published": true}], "size": 2, "snippet_links": [{"key": "after-the-effective-date", "type": "clause", "offset": [24, 48]}, {"key": "will-provide", "type": "clause", "offset": [60, 72]}, {"key": "high-level", "type": "definition", "offset": [89, 99]}, {"key": "summary-development-plan", "type": "definition", "offset": [100, 124]}, {"key": "development-activities", "type": "definition", "offset": [155, 177]}, {"key": "affiliates-and-sublicensees", "type": "clause", "offset": [215, 242]}, {"key": "related-to", "type": "definition", "offset": [243, 253]}, {"key": "approval-of", "type": "definition", "offset": [431, 442]}, {"key": "updated-development-plan", "type": "definition", "offset": [514, 538]}, {"key": "preceding-year", "type": "definition", "offset": [715, 729]}, {"key": "development-of-the", "type": "clause", "offset": [760, 778]}, {"key": "in-addition-to", "type": "clause", "offset": [828, 842]}, {"key": "annual-report", "type": "definition", "offset": [848, 861]}, {"key": "six-month-period", "type": "clause", "offset": [1027, 1043]}, {"key": "the-development-plan", "type": "clause", "offset": [1123, 1143]}, {"key": "sole-discretion", "type": "definition", "offset": [1173, 1188]}, {"key": "subject-to", "type": "clause", "offset": [1190, 1200]}, {"key": "satisfaction-of", "type": "clause", "offset": [1201, 1216]}, {"key": "section-52", "type": "clause", "offset": [1239, 1250]}], "snippet": "Within ninety (90) days after the Effective Date, resTORbio will provide Novartis with a high level summary development plan setting forth the anticipated Development activities to be conducted by resTORbio and its Affiliates and sublicensees related to the Compounds and Products during the following 18 month period (the \u201cDevelopment Plan\u201d). No later than ninety (90) days after each anniversary of the Effective Date, until the approval of the first NDA or MAA for a Product, resTORbio will provide Novartis an updated Development Plan providing, in reasonable detail, the Development activities conducted by resTORbio and its Affiliates and sublicensees related to Compounds and Products during the immediately preceding year and its anticipated plans for Development of the Compounds and Products for next 18 month period. In addition to this annual report, resTORbio will provide to Novartis a high level summary of all Development activities that resTORbio, its agents, or their sublicensees have conducted in the prior six month period until the approval of the first NDA or MAA for a Product. resTORbio may revise the Development Plan or any update thereto in its sole discretion, subject to satisfaction of its obligations under Section 5.2.", "hash": "cfb036ea8e70da98c3508690f75e4987", "id": 8}, {"samples": [{"hash": "bwbwhH2Jg6T", "uri": "/contracts/bwbwhH2Jg6T#development-information", "label": "Limited Liability Company Agreement (Bluerock Residential Growth REIT, Inc.)", "score": 26.1690616608, "published": true}, {"hash": "gbOmpngR6rr", "uri": "/contracts/gbOmpngR6rr#development-information", "label": "Limited Liability Company Agreement (Bluerock Residential Growth REIT, Inc.)", "score": 25.6132793427, "published": true}], "size": 2, "snippet_links": [{"key": "construction-process", "type": "clause", "offset": [11, 31]}, {"key": "tcr-member", "type": "definition", "offset": [37, 47]}, {"key": "will-provide", "type": "clause", "offset": [48, 60]}, {"key": "developer-to-provide", "type": "clause", "offset": [74, 94]}, {"key": "to-the-company", "type": "clause", "offset": [95, 109]}, {"key": "br-member", "type": "definition", "offset": [114, 123]}, {"key": "copies-of-all", "type": "definition", "offset": [124, 137]}, {"key": "related-information", "type": "clause", "offset": [143, 162]}, {"key": "the-loan", "type": "clause", "offset": [167, 175]}, {"key": "not-limited", "type": "clause", "offset": [191, 202]}, {"key": "copies-of-the", "type": "clause", "offset": [214, 227]}, {"key": "construction-draws", "type": "clause", "offset": [228, 246]}, {"key": "access-to-the-property", "type": "clause", "offset": [339, 361]}, {"key": "in-connection-with", "type": "clause", "offset": [399, 417]}, {"key": "development-and-construction-of-the-project", "type": "clause", "offset": [422, 465]}], "snippet": "During the construction process, the TCR Member will provide or cause the Developer to provide to the Company and BR Member copies of all draw-related information for the Loan, including but not limited to monthly copies of the construction draws and construction draws top sheets with budget-versus-actual information, plus full physical access to the Property and all documentation of the Company in connection with the development and construction of the Project.", "hash": "9280998b0709256dd4fbec6533ba49bd", "id": 9}, {"samples": [{"hash": "8TdbGCZYN6r", "uri": "/contracts/8TdbGCZYN6r#development-information", "label": "Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)", "score": 21.0, "published": true}, {"hash": "1Tf64n1GC8B", "uri": "/contracts/1Tf64n1GC8B#development-information", "label": "Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)", "score": 21.0, "published": true}], "size": 2, "snippet_links": [{"key": "development-and-testing", "type": "clause", "offset": [67, 90]}, {"key": "licensed-compounds", "type": "definition", "offset": [98, 116]}, {"key": "necessary-for", "type": "definition", "offset": [187, 200]}, {"key": "in-addition", "type": "clause", "offset": [212, 223]}, {"key": "the-contemplated", "type": "clause", "offset": [304, 320]}, {"key": "regulatory-submissions", "type": "definition", "offset": [400, 422]}, {"key": "prior-to-the", "type": "clause", "offset": [457, 469]}, {"key": "date-of", "type": "clause", "offset": [470, 477]}, {"key": "a-copy-of", "type": "clause", "offset": [499, 508]}, {"key": "regulatory-communication", "type": "definition", "offset": [533, 557]}, {"key": "material-shall-be", "type": "clause", "offset": [604, 621]}, {"key": "subject-to-article-11", "type": "clause", "offset": [622, 643]}], "snippet": "Sankyo shall keep MTI informed as to the progress of Sankyo in the development and testing of all Licensed Compounds and Products and the preparing, filing and obtaining of the approvals necessary for marketing. In addition, Sankyo shall provide MTI with a minimum of three (3) months' advance notice of the contemplated filing of an IND or an NDA. Sankyo shall also provide MTI with a report on all regulatory submissions, communications or meetings on or prior to the date of such submissions and a copy of any INDs, NDAs or other regulatory communication within five (5) days of filing thereof, which material shall be subject to Article 11 hereof except as otherwise set forth herein.", "hash": "2989525eef48aa0dcc8e5ebace76ff47", "id": 10}], "next_curs": "CmASWmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjwLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IiBkZXZlbG9wbWVudC1pbmZvcm1hdGlvbiMwMDAwMDAwYQyiAQJlbhgAIAA=", "clause": {"children": [["reports-and-information-exchange", "Reports and Information Exchange"], ["clinical-and-regulatory-audits", "Clinical and Regulatory Audits"], ["adverse-reaction-reporting", "Adverse Reaction Reporting"], ["ownership-of-pre", "Ownership of Pre"], ["diligence-failure", "Diligence Failure"]], "title": "Development Information", "parents": [["the-development-program", "The Development Program"], ["rights-and-duties-of-managers", "Rights and Duties of Managers"], ["development-and-development-fee", "Development and Development Fee"], ["governance", "Governance"], ["process-for-determining-compound-candidate", "Process for Determining Compound Candidate"]], "size": 73, "id": "development-information", "related": [["client-information", "Client Information", "Client Information"], ["patient-information", "Patient Information", "Patient Information"], ["project-information", "Project Information", "Project Information"], ["management-information", "Management Information", "Management Information"], ["student-information", "Student Information", "Student Information"]], "related_snippets": [], "updated": "2026-02-12T06:00:13+00:00", "also_ask": ["What key disclosures should be mandated in the Development Information clause to protect all parties?", "How can this clause be leveraged to allocate liability for incomplete or inaccurate development data?", "What are the most common negotiation pitfalls or loopholes in Development Information provisions?", "How do courts typically interpret ambiguous or missing Development Information in disputes?", "How does this clause compare to industry standards or statutory requirements for development disclosures?"], "drafting_tip": "Specify the types of development information required to ensure clarity; define disclosure timelines to promote timely communication; outline confidentiality obligations to protect proprietary data.", "explanation": "The Development Information clause outlines the requirements for sharing and disclosing information related to the progress and status of a development project. Typically, it obligates one party\u2014often the developer\u2014to provide regular updates, reports, or access to documentation about the project's milestones, timelines, and any issues encountered. This clause ensures that all stakeholders remain informed and can address potential problems proactively, thereby promoting transparency and effective project management."}, "json": true, "cursor": ""}}